Aplagon Secures $7M to Accelerate First-in-Class Thromboinflammatory Therapeutics Development

Aplagon is proud to announce a significant funding milestone with a successful raise of $7,000,000 that will accelerate our mission of addressing critical unmet needs in vascular medicine. Founded on pioneering research by Riitta Lassila and associates at the Wihuri Research Institute in Helsinki, our clinical-stage biopharmaceutical company has been at the forefront of developing first-in-class therapeutics for thromboinflammatory diseases. This recent infusion of capital reinforces our commitment to advancing innovative treatments that provide targeted, long-term relief for conditions that challenge current therapeutic options. The funding will be strategically deployed to advance our lead therapeutic, APAC—a heparin proteoglycan mimetic with dual antiplatelet and anticoagulant properties—and to propel its clinical development forward. By specifically targeting vascular injury sites, APAC offers a unique approach with localized action that minimizes systemic exposure, positioning it as a promising candidate against thromboinflammatory conditions. Our clinical pipeline is focused on addressing challenging conditions such as arteriovenous fistula (AVF) maturation failure in hemodialysis patients and chronic limb threatening ischemia (CLTI), where there remains an urgent need to mitigate risks of amputations and major cardiovascular events. The new capital will support critical clinical trials and further research initiatives, facilitating rapid translational progress from our esteemed research origins to tangible patient benefits. As we step into this exciting phase of growth, we remain deeply committed to our vision of transforming vascular medicine and improving patient outcomes worldwide through first-in-class therapeutic solutions.